SPDR S&P Biotech ETF
397 hedge funds and large institutions have $3.88B invested in SPDR S&P Biotech ETF in 2017 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 124 increasing their positions, 112 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
3% more capital invested
Capital invested by funds: $3.77B → $3.88B (+$113M)
6% less funds holding in top 10
Funds holding in top 10: 18 → 17 (-1)
71% less call options, than puts
Call options by funds: $537M | Put options by funds: $1.85B
Holders
397
Holding in Top 10
17
Calls
$537M
Puts
$1.85B
Top Buyers
| 1 | +$122M | |
| 2 | +$118M | |
| 3 | +$75.5M | |
| 4 |
Barclays
London,
United Kingdom
|
+$50.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$41.7M |
Top Sellers
| 1 | -$102M | |
| 2 | -$96.7M | |
| 3 | -$59.3M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$41.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$39.9M |